CDK2 and breast cancer: Nevertheless, a novel potent and selective CDK2/4/6 inhibitor, PF-06873600, was recently developed and demonstrated activity in Rb-deficient palbociclib-resistant breast cancer cell models exhibiting high cyclin E expression [82].